Clinical Trials Logo

Clinical Trial Summary

While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities. In a previous study, the authors have demonstrated that 22% of subjects with CPA fulfilled the obligatory criteria for ABPA. While the preferable therapy in patients with ABPA is systemic glucocorticoids, the primary therapy in CPA is oral triazoles. However, a different management protocol in the "overlap group" with low doses of glucocorticoids and triazoles, needs to be systematically explored. In this study the investigators intend to compare the clinical outcomes in subjects with ABPA-CPA overlap treated either with oral azoles or a combination of systemic glucocorticoids and oral azoles.


Clinical Trial Description

Aspergillus causes a variety of pulmonary disorders depending on the host immunity. In immunocompetent hosts, it can cause allergic diseases, the prototype being allergic bronchopulmonary aspergillosis (ABPA). In immunosuppressed host, it causes life-threatening invasive disease. Chronic pulmonary aspergillosis (CPA) represents chronic Aspergillus infection of the pulmonary parenchyma in subjects with normal or slightly suppressed immunity, and generally an underlying structural lung disease (previously treated pulmonary tuberculosis, chronic obstructive pulmonary disease, sarcoidosis, diffuse parenchymal lung disease and others). The diagnosis of CPA is based on the presence of clinical symptoms (low-grade fever, weight loss, malaise, chronic cough, recurrent hemoptysis and others), radiological features (combination of one or more cavities and presence of fungal ball or fibrosis, pericavitary infiltrates, consolidation, nodules and pleural thickening) and the demonstration of either direct (growth of Aspergillus on sputum or bronchoalveolar lavage fluid [BALF] culture) or indirect (elevated serum or BALF galactomannan index or A.fumigatus-specific IgG or precipitin in serum) evidence of Aspergillus infection. Primarily seen in patients with asthma and cystic fibrosis, the diagnosis of ABPA is currently made on the combination of clinical (low grade fever, hemoptysis and others), radiological (bronchiectasis, mucus impaction, centrilobular nodules and others) and immunological (A.fumigatus-specific IgE and IgG, total IgE, and elevated eosinophils) findings. While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities. For example, A.fumigatus-specific IgG and Aspergillus precipitins are used both in diagnosing ABPA and CPA.(10) The culture of respiratory tract secretions can demonstrate the growth of Aspergillus in both these disorders. Also, ABPA is a predisposing condition for developing CPA and it is likely that both ABPA and CPA may coexist. In a previous study, the authors have demonstrated that 22% of subjects with CPA fulfilled the obligatory criteria for ABPA. While CPA is primarily due to dysfunction of Th-1 immunity, ABPA represents an inflammatory response due to Th-2 hyper response. Thus, it is possible that subjects with ABPA-CPA overlap could have components of both heightened inflammatory response and local immune dysfunction thereby perpetuating structural lung damage. While the preferable therapy in patients with ABPA is systemic glucocorticoids, the primary therapy in CPA is oral triazoles. However, a different management protocol in the "overlap group" with low doses of glucocorticoids and triazoles, needs to be systematically explored. In this study the investigators intend to compare the clinical outcomes in subjects with ABPA-CPA overlap treated either with oral azoles or a combination of systemic glucocorticoids and oral azoles. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05444946
Study type Interventional
Source Postgraduate Institute of Medical Education and Research
Contact Inderpaul S Sehgal, MD, DM
Phone 91-172275
Email inderpgi@outlook.com
Status Recruiting
Phase N/A
Start date June 15, 2022
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT01222273 - Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis N/A
Completed NCT04442269 - Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED) Phase 2
Terminated NCT00787917 - An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Phase 4
Completed NCT02273661 - Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). Phase 2
Not yet recruiting NCT05129033 - A Prospective Study on Optimizing Treatment for ABPA N/A
Completed NCT02440009 - A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT01857479 - A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Not yet recruiting NCT06244979 - iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine Phase 2
Completed NCT00585364 - Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA N/A
Completed NCT01621321 - Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Terminated NCT03960606 - Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis Phase 2
Active, not recruiting NCT04227483 - Deflazacort vs. Prednisolone in Acute-stage ABPA Phase 2/Phase 3
Withdrawn NCT05903612 - Allergic Bronchopulmonary Aspergillosis Prescreening Study
Completed NCT04229303 - Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects Phase 1
Completed NCT04476758 - Immune Profiles in CF Fungal Infection
Withdrawn NCT04108962 - Benralizumab in the Treatment of Patients With Severe Asthma With ABPA Phase 4
Recruiting NCT06174922 - A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis Phase 3
Completed NCT01321827 - Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT00974766 - Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Phase 2/Phase 3
Completed NCT03059992 - Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Phase 3